Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2003-03-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 328
- Registration Number
- NCT00056641
- Locations
- πΊπΈ
UT Southwestern, Dallas, Texas, United States
π¨π¦Toronto General Hospital, Toronto, Ontario, Canada
π©πͺBoehringer Ingelheim Investigational Site, Stuttgart, Germany
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-02-10
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 630
- Registration Number
- NCT00054717
- Locations
- πΊπΈ
1182.12.9 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
πΊπΈ1182.12.7 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States
πΊπΈ1182.12.1 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2002-07-24
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00042068
- Locations
- πΊπΈ
Suite 202, Kalamazoo, Michigan, United States
πΊπΈSuite 140, Anchorage, Alaska, United States
πΊπΈSuite 200, Dallas, Texas, United States
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
- Conditions
- Hypertension
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 490
- Registration Number
- NCT00034840
- Locations
- πΊπΈ
National Research Institute, Los Angeles, California, United States
πΊπΈUniversity of Conn. Health Services Center, Hypertension and Vascular Disease, Farmington, Connecticut, United States
πΊπΈUniversity of Maryland/Nephrology Clinical Research Unit, Baltimore, Maryland, United States
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
- Conditions
- HIV Infections
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2005-09-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 165
- Registration Number
- NCT00034866
- Locations
- πΊπΈ
University of So. California / LA County USC Medical Center, Los Angeles, California, United States
πΊπΈAtlanta VA Medical Center, Dept. of ID, Decatur, Georgia, United States
πΊπΈCORE Center, Cook County Hospital, Chicago, Illinois, United States
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
- Conditions
- Arthritis, Juvenile Rheumatoid
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT00034853
- Locations
- πΊπΈ
107.235.8 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
πΊπΈ107.235.10 Texas Scottish Rite Hospital, Dallas, Texas, United States
πΊπΈ107.235.7 Boehringer Ingelheim Investigational Site, Kansas City, Kansas, United States
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00002166
- Locations
- πΊπΈ
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT00000649
- Locations
- πΊπΈ
Univ of Massachusetts, Worcester, Massachusetts, United States
πΊπΈCooper Green Hosp, Birmingham, Alabama, United States
πΊπΈUniv of California / San Diego Treatment Ctr, San Diego, California, United States
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2000
- Registration Number
- NCT00002368
- Locations
- πΊπΈ
Dr G Michael Wool, Los Angeles, California, United States
πΊπΈNorthwestern Univ / Division of Infectious Diseases, Chicago, Illinois, United States
πΊπΈRush Presbyterian / Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT00002323
- Locations
- πΊπΈ
Johns Hopkins Hosp, Baltimore, Maryland, United States
πΊπΈNorthwestern Univ Med School, Chicago, Illinois, United States
πΊπΈUniv TX Galveston Med Branch, Galveston, Texas, United States